UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 9, 2017
OPIANT PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
| Nevada | 000-55330 | 46-4744124 | ||
(State or other jurisdiction of incorporation) | (Commission File Number
| (IRS Employer Identification No.) |
|
| |
401 Wilshire Blvd., 12th Floor Santa Monica, CA |
90401 | |
(Address of Principal Executive Offices)
| (Zip Code) |
(424) 252-4756 |
Registrant’s telephone number, including area code
| (Former name or former address if changed since last report,) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 8.01 | Other Events. |
On March 9, 2017, Opiant Pharmaceuticals, Inc. (the “Company”) issued a press release announcing the issuance by the U.S. Patent and Trademark Office of two new Company patents covering methods of use for NARCAN® Nasal Spray. These patents are listed in the U.S. Food and Drug Administration publication,Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book.
The full text of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
| Exhibit No. | Description |
| 99.1 | Opiant Pharmaceuticals, Inc. Press Release, dated March 9, 2017. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Opiant Pharmaceuticals, Inc. | ||
| Date: March 9, 2017 | By: | /s/Dr. Roger Crystal |
| Name: Dr. Roger Crystal | ||
| Title: Chief Executive Officer |